Back

SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - SGLT2i Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Roberto Tarantini

University Medical Center Utrecht, Utrecht (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Cardiac sodium/hydrogen exchanger (NHE11) as a novel potential target for SGLT2i in heart failure
Doctor I. Gimenez Escamilla (Valencia, ES)
Abstract Slides
Presentation thumbnail
The comparison of composite end-points between SGLT-2 inhibitors and placebo in diabetic patients with heart failure with mildly reduced ejection fraction: a meta-analysis of the literature
Associate Professor T. Cinar (Istanbul, TR)
Abstract Slides
Presentation thumbnail
Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials
Doctor A. Awad (Texas City, US)
Abstract Slides
Presentation thumbnail
SGLT2i uptake among heart failure patients with reduced ejection fraction: ongoing prescriber hesitancy and how to address this.
Doctor B. Soh (Galway, IE)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - SGLT2i

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources